Original articlePancreas, biliary tract, and liverA System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis
Section snippets
Study Design and Ethics Statement
Between 2012 and 2017, a total of 211 adult patients with a diagnosis of AIH were identified at our academic tertiary care hospital (University Medical Center Hamburg-Eppendorf, Hamburg, Germany) who also had at least 1 dual-energy x-ray absorptiometry (DXA) measurement. All patients had a clinical indication according to the evidence-based (S3) guideline for osteoporosis of the German Association of Osteology and the official position of the International Society for Clinical Densitometry.
Demographic and Disease Characteristics of the Study Cohort
The cross-sectional study cohort consisted of 211 consecutive patients diagnosed with AIH that were identified to have had at least 1 BMD measurement at our institution from 2012 to 2017. At the time point of DXA measurement, the mean age of patients was 56.8 (range, 18–93) years. The majority (79.1%) were women, the mean BMI was 27.1 kg/m2, and the mean duration of disease was 91.8 months. Seventeen (8.1%) patients also had additional signs of PBC (variant syndrome). Moreover, 37 (17.5%)
Discussion
This is the largest study investigating the prevalence of osteoporosis in patients with AIH. Overall, osteoporosis was prevalent in 15.6% of AIH patients, while the prevalence of osteoporosis in patients ≥50 years of age was 19.2%. However, the study has some limitations due to its retrospective design and the patient selection for DXA measurement, which was based on medical indication. A total of 241 other AIH patients who were seen at our institution during 2012–2017 did not receive DXA
References (20)
- et al.
The burden of liver disease in Europe: a review of available epidemiological data
J Hepatol
(2013) - et al.
Bone disease in patients with primary sclerosing cholangitis
Gastroenterology
(2011) - et al.
Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis
J Hepatol
(2019) - et al.
Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials
J Hepatol
(2010) - et al.
Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center
Gastroenterology
(2011) - et al.
Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis
J Hepatol
(2016) - et al.
Controlled trial of prednisone and azathioprine in active chronic hepatitis
Lancet
(1973) - et al.
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
J Hepatol
(1999) - et al.
Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis
Clin Gastroenterol Hepatol
(2018) - et al.
Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease
Clin Gastroenterol Hepatol
(2005)
Cited by (14)
Relevanz der detaillierten skelettalen Analyse durch hochauflösende periphere quantitative Computertomographie (HR-pQCT) in der Orthopädie und Unfallchirurgie
2021, Fuss und SprunggelenkCitation Excerpt :These findings indicate that data derived from the distal radius and tibia correlate well even with the rate of fractures at other sites. Besides the characterization of the bone microarchitecture in osteoporosis patients, disease-specific patterns of primarily extra-skeletal diseases like type 2 diabetes mellitus (T2DM) [38], chronic kidney disease [39], or autoimmune liver diseases like primary sclerosing cholangitis [40], primary biliary cholangitis [41], and autoimmune hepatitis [42] have been revealed. For example, in patients with T2DM, decreased cortical parameters were detected compared to patients without T2DM.
Caring for the Bone Health Among Liver Transplant Recipients
2023, Journal of Clinical and Experimental HepatologyIncreased Risk of Osteoporotic Fracture in Patients With Autoimmune Hepatitis
2024, American Journal of GastroenterologyZinc Supplementation and an Improved Quality of Life in Patients with Autoimmune Hepatitis
2024, Internal MedicineOpen challenges in the management of autoimmune hepatitis
2023, Minerva Gastroenterology
Conflicts of interest The authors disclose no conflicts.
- a
Authors share co-first authorship.